High dose controlled-release oxycodone in hospice care

Journal of Pain and Palliative Care Pharmacotherapy

Volumn 20, Issue 4, 2006, Pages 33-39

  Bercovitch, Michaela ^a,b   Adunsky, Abraham ^a,b  

^a SHEBA MEDICAL CENTER   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

Author keywords

Cancer; Controlled release; End of life; Hospice; Opioids; Outcomes; Oxycodone; Pain

Indexed keywords

OXYCODONE;

ADULT; AGED; ANOREXIA; ARTICLE; BONE METASTASIS; CANCER PAIN; CANCER PATIENT; CANCER SURVIVAL; CONSTIPATION; CONTROLLED RELEASE FORMULATION; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG MEGADOSE; FEMALE; HOSPICE CARE; HOSPICE PATIENT; HUMAN; KARNOFSKY PERFORMANCE STATUS; LOG RANK TEST; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; MOOD; NAUSEA; QUALITY OF LIFE; RETROSPECTIVE STUDY; SLEEP PATTERN; SOMNOLENCE; STATISTICAL SIGNIFICANCE; SURVIVAL TIME; VOMITING; XEROSTOMIA;

ANALGESICS, OPIOID; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HOSPICE CARE; HUMANS; MALE; OXYCODONE; PAIN; QUALITY OF LIFE; RETROSPECTIVE STUDIES; SLEEP;

EID: 33845900212     PISSN: 15360288     EISSN: 15360539     Source Type: Journal    
DOI: 10.1300/J354v20n04_06     Document Type: Article

References (25)

1. Cancer Pain Relief. A guide to opioid availability (second edition), Geneva, Switzerland. World Health Organization, 1996.
2. Kaplan R, Winston C, Parris V, Citron ML, Zhukovsky D, Reder RF, Bukcley BJ, Kaiko RF. Comparison of controlled release and immediate-release oxycodone tablets in patients with cancer pain. J Clin Onc, 1998; 16:3230-7.
3. Smith MT, Frazer BR, Carten KN, Nielsen CK, Kamal Saini. Oxycodone has a distinctly different pharmacology from morphine. Eur J Pain (Suppl A), 2001; 135-6.
4. Davis PM, Varga J, Dickenson D, Walsh D, Le Grand BS, Lagmar R. Normal release and controlled-release oxycodone: Pharmacokinetics, pharmacodynamics and controversy. Support Care Cancer, 2003; 11:84-92.
5. Kanmtor TG, Hopper M, Laska E. Adverse effects of commonly ordered oral narcotics. J Clin Pharmacol, 1981; 21:1-8.
6. Kalso E, Vainio A. Morphine and CROXY hydrochloride in the management of cancer pain. Clin Pharmacol Ther, 1990;47:639-46.
7. Passik SD. Responding rationally to recent reports of abuse/diversion of OxyContin. J Pain Sympt Manage, 2001; 21:359-60.
8. Mucci-LoRusso, Berman B, Silberstein P et al. Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: A randomised, double-blind, parallel-group study. Eur J Pain, 1998; 2/3:239-49.
9. Bruera E, Belzile Mpituskin E, Fainsinger R, et al. Randomized double-blind, cross over trial comparing safety and efficacy of controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol,1998;16:3222-9.
10. Lauretti GR, Oliveira GM, Pereira NL. Comparison of sustained-release morphine with sustained-release oxycodone in advanced cancer patients. Br J Cancer 2003; 89(11):1027-30.
11. Bercovitch M, Waller A, Adunsky A. High dose morphine use in the hospice setting: a database survey of patients characteristics and effect on life expectancy. Cancer 1999; 86:871-7.
12. Bercovitch M, Waller A, Adunsky A. Multidimensional continuous pain assessment chart (MCPAC) for terminal cancer patients: a preliminary report. Am J Hosp Palliat Care. 2002; 19(6):419-25.
13. Bruera E, Schoeller T, Wenk R, MacEachem T, Marcellino S, Hanson J. et al. A prospective multicenter assessment of the Edmonton staging system for cancer pain. J Pain Symptom Manage 1995; 10:348-55.
14. Kaiko R, Lacouture P, Hopf K, Brown J, Goldenhaim P, Jean Brown Associates. Analgesic onset and potency of oral controlled-release (CR) oxycodone and CR morphine (Abstract) Clin Pharmacol Ther 1996: 59-130.
15. Curtis GB, Johnson GH, Clark P Brown J, O'Callaghan R, Shi M, Lacouture PG. Relative Potency of controlled-release oxycodone and controlled-release morphine in postoperative pain model. Eur J Clin Pharmacol 1999; 55:425-9.
16. Karnofsky DA, Albeman WH, Craver LF et al. The use of nitrogen mustards in the treatment of carcinoma. Cancer 1948;1: 634-56.
17. SPSS for Windows software. Version 11, 2001, Chicago.
18. Bercovitch M, Adunsky A. Patterns of high-dose morphine use in a home care hospice service. Should we be afraid of it? Cancer 2004; 101(6):1473-7.
19. Rees WD. Opioid needs of terminal care patients: Variations with age and primary site. Clin Oncol R coll Radiol 1990; 2:79-83.
20. Mercadante S, Cassucuo A, Pumo S, Fulfaro F. Factors influencing the opioid response in advanced cancer patients with pain followed at home: the effect of age and gender. Support Care Cancer 2000; 8(2):123-30.
21. Hall S, Gallagher RM, Gracely E, Knowlton C, Wescules D. The terminal cancer patient: Effects of age, gender, and primary tumor site on opioid dose. Pain Med 2003; 4(2)125-34.
22. Stambaugh JE, Reder RF, Stanbaugh MD, Stanbaugh H, Davis M. Double blind, randomized comparison of the analgesic and pharmacokinetic profiles of controlled and immediate-release oral oxycodone in cancer patients. J Clin Pharmacol 2001; 41:500-6.
23. Watson CPN, Babul N. Efficacy of CROXY in neuropathic pain: A randomized trial in post-herpetic neuralgia. Neurology 1998; 50:1837-41.
24. Hagen ND, Babul N. Comparative clinical efficacy and safety of a novel controlled release oxycodone formulation and controlled release hydromorphone in the treatment of cancer pain. Cancer 1997; 79:1428-37.
25. Christakis NA, Escarce JJ. Survival of Medicare patients after enrollment in hospice programs. N Engl J Med 1996; 335:172-8.